Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
The Japan unit of Sanofi said on April 16 that its president Takahiko Iwaya will step down, effective June 30, after helming the subsidiary for over six years, with a selection process for his successor now underway. Iwaya assumed the…
To read the full story
Related Article
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- Iwaya Reappointed as EFPIA Japan Chair for 2-Year Term
April 1, 2025
- EFPIA Japan Appoints Sanofi’s Takahiko Iwaya as New Chair
August 25, 2021
- Takahiko Iwaya to Take Over as Sanofi Japan President on Jan. 1
December 20, 2019
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- Japan OTC Market Falls for 4th Straight Month in June: Intage
July 29, 2026
- J-TEC, OSferionBiomaterials Join Forces to Expand Knee OA Business
July 29, 2026
- FunPep Allergy Vaccine Misses Exploratory Efficacy Goals in PI
July 29, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…